CancerDrs Find care

Thyroid Cancer clinical trials in Missouri

8 actively recruiting thyroid cancer trials at 21 sites across Missouri.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BR…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06475989
Sites in Missouri:
  • Saint Louis Cancer and Breast Institute-Ballwin — Ballwin, Missouri
  • Central Care Cancer Center - Bolivar — Bolivar, Missouri
  • Cox Cancer Center Branson — Branson, Missouri
  • Southeast Cancer Center — Cape Girardeau, Missouri
  • Freeman Health System — Joplin, Missouri
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Missouri:
  • Local Institution - 2147 — Bolivar, Missouri
  • Washington University Infusion Center Pharmacy — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Missouri:
  • Washington University — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

This open-label, randomized phase II trial evaluates the dose delivery, tolerance, and efficacy of two dosing regimens of lenvatinib among patients with radioactive iodine resistant (RAIR) differentiated thyroid cancer (DTC).

Sponsor: Washington University School of Medicine
NCT ID: NCT07092514
Sites in Missouri:
  • Washington University School of Medicine — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

SLV-154 Treatment of Metastatic Solid Tumors

This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.

Sponsor: Solve Therapeutics
NCT ID: NCT06771219
Sites in Missouri:
  • Washington University — St Louis, Missouri
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Missouri:
  • Mercy Oncology and Hematology - Clayton-Clarkson — Ballwin, Missouri
  • Central Care Cancer Center - Bolivar — Bolivar, Missouri
  • Cox Cancer Center Branson — Branson, Missouri
  • Mercy Cancer Center - Cape Girardeau — Cape Girardeau, Missouri
  • Saint Francis Medical Center — Cape Girardeau, Missouri
View on ClinicalTrials.gov →
NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Missouri:
  • Saint Louis Cancer and Breast Institute-Ballwin — Ballwin, Missouri
  • Central Care Cancer Center - Bolivar — Bolivar, Missouri
  • Cox Cancer Center Branson — Branson, Missouri
  • Saint Francis Medical Center — Cape Girardeau, Missouri
  • Southeast Cancer Center — Cape Girardeau, Missouri
View on ClinicalTrials.gov →
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Missouri:
  • Saint Luke's Cancer Institute, East — Kansas City, Missouri
  • Saint Luke's Cancer Institute — Kansas City, Missouri
  • Saint Luke's Cancer Institute, Kansas City North — Kansas City, Missouri
  • Saint Luke's Cancer Institute, Liberty — Liberty, Missouri
  • North Kansas City Hospital — North Kansas City, Missouri
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20